Acceso abierto

Systemic inflammation, TNM staging and survival in patients with lung cancer

Ionela Erhan

Ionela Erhan

”Dr. Carol Davila” Central Military Emergency Universitary Hospital BucharestRomania
Buscar este autor en
Sciendo|Google Scholar
Erhan, Ionela
, 
Stefan Dumitrache-Rujinski

Stefan Dumitrache-Rujinski

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Buscar este autor en
Sciendo|Google Scholar
Dumitrache-Rujinski, Stefan
, 
Claudia Toma

Claudia Toma

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Buscar este autor en
Sciendo|Google Scholar
Toma, Claudia
 y 
Miron Bogdan

Miron Bogdan

  • Carol Davila University of Medicine and PharmacyBucharest, Romania
  • Marius Nasta Institute of PulmonologyBucharest, Romania
Buscar este autor en
Sciendo|Google Scholar
Bogdan, Miron
  
31 dic 2020
Systemic inflammation, TNM staging and survival in patients with lung cancer's Cover Image
Acerca de este artículo
Artículo anterior
Artículo siguiente
Cite
Descargar portada
Categoría del artículo: Original Papers
Publicado en línea: 31 dic 2020
Páginas: 81 - 86
DOI: https://doi.org/10.2478/pneum-2020-0016
Palabras clave
© 2020 Ionela Erhan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Difference between NLR, PLR and ESR values in resectable versus nonresectable stages.
Difference between NLR, PLR and ESR values in resectable versus nonresectable stages.

Figure 2

Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group A (resectable stages of lung cancer).
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group A (resectable stages of lung cancer).

Figure 3

Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group B (nonresectable stages of lung cancer).
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group B (nonresectable stages of lung cancer).

The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)

NLRPLRESR (mm/h)
Subset As (survivors, n=11)2,36 (0,87–8.36)138,82 (21,61–416,66)15 (6–110)
Subset Ad (deceased, n=20)2,77 (1,25–12,94)132,57 (41,11–371,17)62 (11–135)
Subset Bs (survivors, n=8)1,40 (1,32–1,73)112,89 (91,14–140,54)31 (9–90)
Subset Bd (deceased, n=63)3,59 (0,70–26,60)183,50 (3,38–651,25)44 (3–120)

Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer

102 patientsAge (years)History of smoking (No, %)PA (No)Ne (/mm3)Ly (/mm3)PI (/mm3)NLRPLRESR (mm/h)
Group A (resectable stages) 31 (23 men)65 (51–83)23 74,2%40 (3–100)6380 (2600-22.000)2000 (1020-13.600)294.000 (111.000–709.000)2,74 (0,87–12,94)133,95 (21,61–416,66)35 (6–135)
Group B (nonresectable stages) 71 (63 men)67 (37–88)60 84,5%40 (4–90)6450 (1800–27.892)1800 (500–15.700)327.000 (23.000–661.000)3,51 (0,76–25,60)170,37 (3.38–651,25)40 (3–120)
Idioma:
Inglés
Calendario de la edición:
Volume Open
Temas de la revista:
Medicina, Medicina Clínica, Medicina Clínica, otros, Medicina Interna, Neumología
RSS Feed de revista